Compare Medtronic PLC (MDT) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Primo Brands Corporation Class A Common Stock — how do they compare? Medtronic PLC trades at $95.2 (market cap $118.97B), while Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B). The key difference: Medtronic PLC is far larger — about 17.4× Primo Brands Corporation Class A Common Stock's market cap, and Medtronic PLC pays the higher dividend (3.1%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| MDT | PRMB | |
|---|---|---|
Market Cap | $118.97B | $6.84B |
Volume | 24,932,018 | 2,864,594 |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $25.39 |
52-Week Low | $73.75 | $14.46 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $138.31B | $12.17B |
Dividend Yield | 3.1% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
